Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases
DA Katzka, EV Loftus Jr… - Clinical Pharmacology & …, 2012 - Wiley Online Library
DA Katzka, EV Loftus Jr, M Camilleri
Clinical Pharmacology & Therapeutics, 2012•Wiley Online LibraryNovel treatments for gastrointestinal (GI) diseases are based on molecular targets. Novel
pharmacologic and biological agents with greater selectivity and specificity are being
developed for a variety of epithelial diseases, including eosinophilic esophagitis (EoE),
gastroesophageal reflux disease (GERD), celiac disease, short bowel syndrome (SBS), and
inflammatory bowel diseases (IBDs; Crohn's disease and ulcerative colitis). Motility and
secretory agents are being developed for gastroparesis, irritable bowel syndrome (IBS) …
pharmacologic and biological agents with greater selectivity and specificity are being
developed for a variety of epithelial diseases, including eosinophilic esophagitis (EoE),
gastroesophageal reflux disease (GERD), celiac disease, short bowel syndrome (SBS), and
inflammatory bowel diseases (IBDs; Crohn's disease and ulcerative colitis). Motility and
secretory agents are being developed for gastroparesis, irritable bowel syndrome (IBS) …
Novel treatments for gastrointestinal (GI) diseases are based on molecular targets. Novel pharmacologic and biological agents with greater selectivity and specificity are being developed for a variety of epithelial diseases, including eosinophilic esophagitis (EoE), gastroesophageal reflux disease (GERD), celiac disease, short bowel syndrome (SBS), and inflammatory bowel diseases (IBDs; Crohn's disease and ulcerative colitis). Motility and secretory agents are being developed for gastroparesis, irritable bowel syndrome (IBS), functional constipation, and diarrhea. Here we focus on data from clinical trials involving validated pharmacodynamic or patient response outcomes.
Clinical Pharmacology & Therapeutics (2012); 92 3, 306–320. doi:10.1038/clpt.2012.77
Wiley Online Library